Royal Bank Of Canada Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Posted by Brenda Bartman on Oct 8th, 2026

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target decreased by analysts at Royal Bank Of Canada from $19.00 to $17.00 in a report released on Thursday, Benzinga reports. The firm presently has a “sector perform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price target suggests a potential downside of 2.53% from the stock’s previous close.

SRPT has been the topic of several other research reports. Piper Sandler lowered their price objective on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a report on Thursday, July 9th. JPMorgan Chase & Co. lowered their price target on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, September 30th. Needham & Company LLC reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a research report on Monday, September 28th. Zacks Research cut shares of Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday. Finally, Wall Street Zen lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Seven investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and eight have issued a Sell rating to the company. According to MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Reduce” and an average target price of $22.59.

Get Our Latest Report on SRPT

Sarepta Therapeutics Trading Down 0.3%

SRPT traded down $0.06 during trading on Thursday, reaching $17.44. 109,181 shares of the stock traded hands, compared to its average volume of 3,043,502. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55. The stock’s 50-day moving average is $19.10 and its 200 day moving average is $18.82. Sarepta Therapeutics has a 12 month low of $14.68 and a 12 month high of $24.68. The stock has a market capitalization of $1.84 billion, a PE ratio of -6.00, a P/E/G ratio of 0.27 and a beta of 0.38.

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The business had revenue of $401.25 million during the quarter, compared to analysts’ expectations of $366.39 million. During the same quarter last year, the firm posted $2.02 earnings per share. The firm’s revenue was down 34.3% on a year-over-year basis. Equities analysts anticipate that Sarepta Therapeutics will post 3.27 earnings per share for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Tidal Investments LLC bought a new position in Sarepta Therapeutics during the second quarter valued at $183,000. Baird Financial Group Inc. lifted its position in shares of Sarepta Therapeutics by 7.6% during the 2nd quarter. Baird Financial Group Inc. now owns 12,805 shares of the biotechnology company’s stock valued at $230,000 after buying an additional 901 shares during the last quarter. Nykredit A S purchased a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at $43,000. Corient Private Wealth LP grew its stake in shares of Sarepta Therapeutics by 273.4% during the 2nd quarter. Corient Private Wealth LP now owns 36,712 shares of the biotechnology company’s stock worth $660,000 after acquiring an additional 26,880 shares during the period. Finally, Amundi purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth about $350,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

(Get Free Report)

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs include RNA-based therapies, gene therapy and other genetic medicine approaches designed to address the underlying causes of serious genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for certain patients with DMD mutations, as well as Elevidys, a gene therapy for eligible patients with Duchenne muscular dystrophy.